Navigation Links
VTT searches for novel biomarkers and targets for preventing or treating Type 2 diabetes
Date:2/21/2012

VTT is participating in two new European projects focusing on type 2 diabetes. The projects aim at identifying new therapeutic choices and strategies for preventing the disease. Focus is on obtaining information on cellular dysfunction in diabetes and the effects of changes in lifestyle. The goal includes planning individual lifestyle instructions for people at high risk of diabetes and exploiting the results in a major European health insurance system.

The EU BetaBAT project aims at developing individual therapeutic choices for type 2 diabetics by identifying the connection between the genome and individual cell-level changes causing the disease. The scientists will use systems biological tools to boost the capacity of beta cells and brown adipocytes for regaining homeostatic control.

The other EU project, DEXLIFE, aims at disease prevention by identifying novel diagnostic and predictive biomarkers to detect the progression toward type 2 diabetes in individuals at high risk of the disease. Large-scale data will be acquired during the project, including information on genes and metabolites. The intervention aiming at type 2 diabetes prevention will be set up in the real-life context of a major European health insurance system.

In both projects VTT leads the work packages on integration and modelling of data. VTT has a central role in applying systems biology strategies including metabolomics, integrative bioinformatics and biosystems modelling to identify putative organelle-specific targets (BetaBAT) and early predictive markers of type 2 diabetes progression (DEXLIFE).

The global prevalence of diabetes has reached 285 million and is projected to rise to 435 million by 2030. Type 2 diabetes is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of type 2 diabetes are huge, approaching 10% of all health costs.


'/>"/>

Contact: Matej Oresic
matej.oresic@vtt.fi
358-207-224-491
VTT Technical Research Centre of Finland
Source:Eurekalert

Related biology news :

1. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
2. Trauma drama: K-State professor researches drama queen of immune system
3. A Spanish botanist searches for prehistoric flora refuges in China
4. AZTI-Tecnalia researches the use of vegetable by-products for animal feed
5. Scientists identify novel inhibitor of human microRNA
6. Conaway Lab identifies novel mechanism for regulation of gene expression
7. LIAI launches new division to look at novel approaches to heart disease and inflammation
8. Childrens National researchers develop novel anti-tumor vaccine
9. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
10. Novel publishing approach puts textbook in more hands
11. GEN reports on novel tools for deciphering biological networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...   Biostage, Inc. (Nasdaq: BSTG ... bioengineered organ implants to treat cancers and other life-threatening ... the closing on February 15, 2017 of its previously ... and warrants to purchase 20,000,000 shares of common stock, ... was priced at $0.40 per share of common stock, ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... LAFAYETTE, Indiana (PRWEB) , ... ... ... division of Albany Molecular Research Inc. has further extended its industry leading ... This service offers state-of-the-art cGMP techniques and methods for the ...
Breaking Biology Technology: